Gelesis

Biotech & Life Sciences · Boston, United States · Founded 2006 · Public via SPAC 2021

Biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients MoreLess

Gelesis is a biotechnology company focused on developing innovative therapies for gastrointestinal (GI) related chronic diseases. The company's proprietary platform features the first and only superabsorbent hydrogel made exclusively from naturally derived building blocks. Gelesis primarily serves adults who are overweight or obese, with a Body Mass Index (BMI) of 25 to 40, by offering products like PLENITY, which aids in weight management when combined with diet and exercise. The company operates in the healthcare and biotechnology market, targeting conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Type 2 diabetes, and Chronic Idiopathic Constipation (CIC). Gelesis generates revenue through the sale of its hydrogel-based therapies and continues to expand its pipeline of potential treatments for various GI-related conditions.

Keywords: biotechnology, hydrogel, gastrointestinal, obesity, weight management, chronic diseases, NAFLD, NASH, Type 2 diabetes, CIC.

Valuation $0–100M

Revenue $10–50M

Headcount <100

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Talent graph

Gelesis's talent

Book a demo to see the people

Team profiled 15 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Gelesis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

BIRD Foundation

Series A 3 investors entered at this stage

PureTech

QIC BioVentures

OrbiMed

Series B+ 9 investors entered at this stage

Cormorant Asset Management

Invesco

Vitruvian Partners

China Medical System Holdings

PV Capital Management

Pacific investment Management

Kennedy Lewis Investment Management

Capstar Special Purpose Acquisition Corp

Theras

Global footprint

Where Gelesis has talent and traffic

Workforce by country

4 countries with
team presence

🇮🇹 Italy87.9%

🇺🇸 United States6.1%

🇬🇧 United Kingdom3%

🇮🇱 Israel3%

4 countries shown

Web traffic by country

2.4K monthly visits
across markets

🇺🇸 United States54.2%

🇮🇹 Italy50%

Top 2 markets shown

Patent intelligence

$47M patent portfolio · 18 active families

Estimated portfolio value

$47M

88.0% of market cap · 4.9× smaller than top peer Ascendis Pharma ($234M)

18 active patent families

Where Gelesis innovates Carboxylic acidCarboxymethyl celluloseCelluloseComposite materialGastric fluid

Where Gelesis concentrates vs peers

Each axis is a top-10 topic across Gelesis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Gelesis

An AI-synthesized read of the highest-engagement posts about Gelesis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gelesis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles